Phase 2 RCT in 70 patients with previously treated HR-positive, HER2-negative metastatic breast cancer: palbociclib 100 mg vs 125 mg with endocrine therapy cut grade ≥3 neutropenia (33% vs 56%; P=0.04). Median PFS 6.28 vs 9.28 months, not significant.
RCTn = 70 patients
Jacob et al. TBCRC 035: randomized phase II pharmacodynamic study of standard and reduced-dose palbociclib with endocrine therapy in hormone receptor (HR)-positive previously treated metastatic breast cancer